keyword
MENU ▼
Read by QxMD icon Read
search

Xeomin

keyword
https://www.readbyqxmd.com/read/28657917/patient-registry-of-spasticity-care-world-data-analysis-based-on-physician-experience
#1
Alberto Esquenazi, Stella Lee, Nathaniel Mayer, Roser Garreta, Atul Patel, Elie Elovic, Stephen Koelbel, Gerard Francisco, Iris Reuter
OBJECTIVE: The aim of the study was to report physician experience-based "real-world" treatment patterns with botulinum toxin type A in patients with stroke and traumatic brain injury. DESIGN: A prospective, multicenter, international observational registry design was used. RESULTS: Six hundred twenty-seven participants with stroke and 132 participants with traumatic brain injury were assessed and treated by 17 more experienced physicians and 12 less experienced physicians...
June 28, 2017: American Journal of Physical Medicine & Rehabilitation
https://www.readbyqxmd.com/read/28639368/botulinum-toxin-state-of-the-art
#2
REVIEW
Joseph Jankovic
Botulinun neurotoxin (BoNT) has emerged as one of the most multipurpose therapeutic agents in modern medicine with more clinical applications than any other drug currently on the market. Initially developed in the treatment of strabismus and neurologic movement disorders, the use of botulinun neurotoxin has been expanding during the past 3 decades to include the treatment of a variety of ophthalmologic, gastrointestinal, urologic, orthopedic, dermatologic, dental, secretory, painful, cosmetic, and other conditions...
June 22, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28440002/differential-effect-of-incobotulinumtoxin-a-on-pain-neurogenic-flare-and-hyperalgesia-in-human-surrogate-models-of-neurogenic-pain
#3
S A Diener, M Breimhorst, Th Vogt, H H Krämer, P D Drummond, C Geber, F Birklein
BACKGROUND: The effectiveness of Botulinum-neurotoxin A (BoNT/A) to treat pain in human pain models is very divergent. This study was conducted to clarify if the pain models or the route of BoNT/A application might be responsible for these divergent findings. METHODS: Sixteen healthy subjects (8 males, mean age 27 ± 5 years) were included in a first set of experiments consisting of three visits: (1) Visit: Quantitative sensory testing (QST) was performed before and after intradermal capsaicin injection (CAPS, 15 μg) on one thigh and electrical current stimulation (ES, 1 Hz) on the contralateral thigh...
April 25, 2017: European Journal of Pain: EJP
https://www.readbyqxmd.com/read/28290229/incobotulinumtoxina-injection-for-temporomandibular-joint-disorder
#4
RANDOMIZED CONTROLLED TRIAL
Amit A Patel, Michael Z Lerner, Andrew Blitzer
OBJECTIVES: Temporomandibular disorder (TMD) involves dysfunction of the temporomandibular joint and associated muscles of mastication causing pain with chewing, limitation of jaw movement, and pain. While the exact pathophysiology of TMD is not completely understood, it is thought that hyperfunction of the muscles of mastication places stress on the temporomandibular joint, leading to degeneration of the joint and associated symptoms. We hypothesize that chemodenervation of the muscles of mastication with IncobotulinumtoxinA (Xeomin) will decrease the stress on the temporomandibular joint and improve pain associated with temporomandibular joint and muscle disorder (TMJD)...
April 2017: Annals of Otology, Rhinology, and Laryngology
https://www.readbyqxmd.com/read/28283596/safety-and-efficacy-of-incobotulinumtoxina-doses-up-to-800-u-in-limb-spasticity-the-tower-study
#5
MULTICENTER STUDY
Jörg Wissel, Djamel Bensmail, Joaquim J Ferreira, Franco Molteni, Lalith Satkunam, Susana Moraleda, Tiina Rekand, John McGuire, Astrid Scheschonka, Birgit Flatau-Baqué, Olivier Simon, Edward T J Rochford, Dirk Dressler, David M Simpson
OBJECTIVE: To evaluate safety (primary objective) and efficacy of increasing doses (400 U up to 800 U) of incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals GmbH) for patients with limb spasticity. METHODS: In this prospective, single-arm, dose-titration study (NCT01603459), patients (18-80 years) with spasticity due to cerebral causes, who were clinically deemed to require total doses of 800 U incobotulinumtoxinA, received 3 consecutive injection cycles (ICs) with 400 U, 600 U, and 600-800 U incobotulinumtoxinA, respectively, each followed by 12-16 weeks' observation...
April 4, 2017: Neurology
https://www.readbyqxmd.com/read/28253424/botulinum-toxin-for-the-treatment-of-strabismus
#6
REVIEW
Fiona J Rowe, Carmel P Noonan
BACKGROUND: The use of botulinum toxin as an investigative and treatment modality for strabismus is well reported in the medical literature. However, it is unclear how effective it is in comparison to other treatment options for strabismus. OBJECTIVES: The primary objective was to examine the efficacy of botulinum toxin therapy in the treatment of strabismus compared with alternative conservative or surgical treatment options. This review sought to ascertain those types of strabismus that particularly benefit from the use of botulinum toxin as a treatment option (such as small angle strabismus or strabismus with binocular potential, i...
March 2, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27747444/safety-of-botulinum-toxin-short-interval-therapy-using-incobotulinumtoxin-a
#7
Dirk Dressler, Fereshte Adib Saberi
The therapeutic efficacy of botulinum toxin (BT) can be completely blocked by formation of BT antibodies (BTAB), thus producing antibody-induced therapy failure (ABTF). One of the risk factors for this is the interval between two subsequent injection series. To prevent BTAB formation it is universally recommended not to use interinjection intervals of less than 12 weeks. However, BT's therapeutic efficacy may be considerably shorter than this interval, thus causing substantial reduction of quality of life...
April 2017: Journal of Neural Transmission
https://www.readbyqxmd.com/read/27676911/therapeutic-benefit-of-botulinum-toxin-a-for-the-spasticity-of-the-triceps-surae-in-patients-with-multiple-sclerosis-an-observational-study
#8
Philippe Gallien, Benoit Nicolas, Leblong Emilie, Sabine Petrilli, Sandrine Robineau, Aurelie Durufle, Katell Autret, Tiphaine Berthier, Lucie Chochina, Bastien Fraudet, Corinne Pfeiffer
INTRODUCTION: Few data are available on the use of botulinum toxin for spasticity treatment in multiple sclerosis. In a previous study, we found that one of the main therapeutic goals was the improvement ok walking, in patients suffering from spasticity of the triceps surae. OBJECTIVE: This is a pilot observational study, with the aim to assess the benefit of an injection of 200 UI of incobotulinumtoxin A in multiple sclerosis patients suffering from spasticity du triceps surae...
September 2016: Annals of Physical and Rehabilitation Medicine
https://www.readbyqxmd.com/read/27673516/advancements-and-refinement-in-facial-neuromodulators
#9
Reza Kordestani, Kevin H Small, Rod J Rohrich
The use of neuromodulators has increased by approximately 748 percent from 2000 to 2014 and has become an integral adjunct for facial rejuvenation. Knowledge of facial anatomy, accurate facial analysis, and familiarity with neurotoxin characteristics will minimize complications and optimize results. Current U.S. Food and Drug Administration-approved neurotoxins in the United States include onabotulinumtoxin A (Botox), abobotulinumtoxin A (Dysport), and incobotulinumtoxin A (Xeomin). The dosage and effect of these products are not interchangeable, so practitioners should master the utility and response of one product before trying the other products...
October 2016: Plastic and Reconstructive Surgery
https://www.readbyqxmd.com/read/27633917/gender-differences-in-onabotulinum-toxin-a-dosing-for-adductor-spasmodic-dysphonia
#10
Michael Z Lerner, Benjamin A Lerner, Amit A Patel, Andrew Blitzer
OBJECTIVES/HYPOTHESIS: The objective of this study was to determine the influence of gender on onabotulinum toxin A dosing for the treatment of adductor spasmodic dysphonia symptoms. STUDY DESIGN: Retrospective review. METHODS: A chart review of the senior author's database of botulinum toxin injections was performed. Patients diagnosed with adductor spasmodic dysphonia who received onabotulinum toxin A (BoNTA) injections to the thyroarytenoid muscle for at least 5 years were included for study...
May 2017: Laryngoscope
https://www.readbyqxmd.com/read/27530616/incobotulinumtoxina-a-review-in-upper-limb-spasticity
#11
REVIEW
Yvette N Lamb, Lesley J Scott
Intramuscular incobotulinumtoxinA (Xeomin(®)) is indicated for the treatment or improvement of adult patients with upper limb spasticity (featured indication), cervical dystonia, blepharospasm and glabellar lines. It is a highly purified formulation of botulinum toxin type A that inhibits acetylcholine signalling at neuromuscular junctions, reducing muscle hypertonia. This narrative review discusses the clinical use of incobotulinumtoxinA in adults with upper limb spasticity and summarizes its pharmacological properties...
September 2016: Drugs
https://www.readbyqxmd.com/read/27461432/impact-of-botulinum-toxin-a-injection-on-esophageal-anastomosis-in-a-rabbit-model
#12
Yoshiko Usui, Shigeru Ono
PURPOSE: The management of esophageal atresia is established, but the rate of postoperative complications remains high. We focused on a new, recently reported method of esophageal elongation using botulinum toxin type A (BTX-A) and evaluated the efficacy of BTX-A injection around esophageal anastomoses with tension in a rabbit model. METHODS: Twenty rabbits aged 8-10 weeks and weighing 1.27-1.72 kg underwent resections of the esophagus measuring 1.5 cm long using an anterior cervical approach...
September 2016: Pediatric Surgery International
https://www.readbyqxmd.com/read/27363760/overview-of-botulinum-toxins-for-aesthetic-uses
#13
REVIEW
Michael S Gart, Karol A Gutowski
Botulinum toxin type A (BTA) can be used for facial aesthetics. The 3 currently available BTA types include onabotulinumtoxinA (Botox; Botox Cosmetic, Allergan, Irvine, CA), abobotulinumtoxinA (Dysport; Ipsen, Ltd, Berkshire, UK), and incobotulinumtoxinA (Xeomin; Merz Pharmaceuticals, Frankfurt, Germany). The mechanism of action and clinical uses for treatment of dynamic lines of the forehead, brow, glabella, lateral orbit, nose, and lips are presented, as well as treatment of masseter hypertrophy, platysmal bands, and improvements of the perioral region...
July 2016: Clinics in Plastic Surgery
https://www.readbyqxmd.com/read/27177451/safety-profile-of-incobotulinum-toxin-a-xeomin-%C3%A2-in-gastrocnemious-muscles-injections-in-children-with-cerebral-palsy-randomized-double-blind-clinical-trial
#14
RANDOMIZED CONTROLLED TRIAL
Elena Carraro, Enrico Trevisi, Andrea Martinuzzi
BACKGROUND: The only two preparations of botulinum toxin A for which there are published evidences of efficacy in children with cerebral palsy are onabotulinum toxin A (Botox(®)) and abobotulinum toxin A (Dyport(®)); these toxins should be considered generally safe and appropriate in the treatment for localized upper and lower limb spasticity. AIMS: To establish the safety profile of incobotulinum toxin A (Xeomin(®)) in children with cerebral palsy and muscle spasticity...
July 2016: European Journal of Paediatric Neurology: EJPN
https://www.readbyqxmd.com/read/27119918/a-quantitative-analysis-of-onabotulinumtoxina-abobotulinumtoxina-and-incobotulinumtoxina-a-randomized-double-blind-prospective-clinical-trial-of-comparative-dynamic-strain-reduction
#15
RANDOMIZED CONTROLLED TRIAL
Anthony J Wilson, Brian Chang, Anthony J Taglienti, Bianca C Chin, Catherine S Chang, Nancy Folsom, Ivona Percec
BACKGROUND: U.S. Food and Drug Administration-approved formulations of botulinum toxin include onabotulinumtoxinA (Botox; Allergan, Inc., Irvine, Calif.), abobotulinumtoxinA (Dysport; Galderma Pharma S.A., Lausanne, Switzerland), and incobotulinumtoxinA (Xeomin; Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany). This study uses digital image correlation to compare dynamic strain reduction between available neurotoxins. METHODS: Seventy-three treatment-naive female patients aged were randomized to injection with onabotulinumtoxinA (20 units), abobotulinumtoxinA (60 units), or incobotulinumtoxinA (20 units) in the glabella...
May 2016: Plastic and Reconstructive Surgery
https://www.readbyqxmd.com/read/27021747/cost-effectiveness-of-incobotulinumtoxin-a-with-flexible-treatment-intervals-compared-to-onabotulinumtoxin-a-in-the-management-of-blepharospasm-and-cervical-dystonia
#16
Dominic Tilden, Carmel Guarnieri
BACKGROUND: Incobotulinumtoxin-A (Xeomin(®), Merz Pharmaceuticals, Sydney, New South Wales) is a formulation of botulinum neurotoxin type A that is free of complexing proteins. OBJECTIVE: To assess the cost-effectiveness of incobotulinumtoxin-A administered with flexible treatment intervals compared to onabotulinumtoxin-A (Botox(®), Sydney, New South Wales) in blepharospasm and cervical dystonia from the perspective of Australian health care providers. METHODS: A Markov state transition model was developed to perform a cost-utility analysis to compare the cost and health benefits of incobotulinumtoxin-A to that of onabotulinumtoxin-A...
March 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27002815/botulinum-toxin-therapy-reduction-of-injection-site-pain-by-ph-normalisation
#17
Dirk Dressler, Fereshte Adib Saberi, Hans Bigalke
Botulinum toxin (BT) is injected intramuscularily and may produce injection site pain (ISP). We wanted to explore whether the pH value of the reconstituted BT drug contributes to ISP and, if so, what strategies can be applied to reduce it. In part 1 of the study, pH values of different reconstitution solutions and of major BT drugs reconstituted with different reconstitution solutions were assessed. In part 2, the effects of reconstitution with normal saline (NS) and Ringer acetate (RA) were compared intraindividually and in a double blind fashion in 34 patients with blepharospasm...
May 2016: Journal of Neural Transmission
https://www.readbyqxmd.com/read/26959061/conversion-ratio-between-botox%C3%A2-dysport%C3%A2-and-xeomin%C3%A2-in-clinical-practice
#18
REVIEW
Francesco Scaglione
Botulinum neurotoxin has revolutionized the treatment of spasticity and is now administered worldwide. There are currently three leading botulinum neurotoxin type A products available in the Western Hemisphere: onabotulinum toxin-A (ONA) Botox(®), abobotulinum toxin-A (ABO), Dysport(®), and incobotulinum toxin A (INCO, Xeomin(®)). Although the efficacies are similar, there is an intense debate regarding the comparability of various preparations. Here we will address the clinical issues of potency and conversion ratios, as well as safety issues such as toxin spread and immunogenicity, to provide guidance for BoNT-A use in clinical practice...
March 4, 2016: Toxins
https://www.readbyqxmd.com/read/26914922/a-mixed-treatment-comparison-to-compare-the-efficacy-and-safety-of-botulinum-toxin-treatments-for-cervical-dystonia
#19
Yi Han, Andrea L Stevens, Khashayar Dashtipour, Robert A Hauser, Zoltan Mari
A systematic pair-wise comparison of all available botulinum toxin serotype A and B treatments for cervical dystonia (CD) was conducted, as direct head-to-head clinical trial comparisons are lacking. Five botulinum toxin products: Dysport(®) (abobotulinumtoxinA), Botox(®) (onabotulinumtoxinA), Xeomin(®) (incobotulinumtoxinA), Prosigne(®) (Chinese botulinum toxin serotype A) and Myobloc(®) (rimabotulinumtoxinB) have demonstrated efficacy for managing CD. A pair-wise efficacy and safety comparison was performed for all toxins based on literature-reported clinical outcomes...
April 2016: Journal of Neurology
https://www.readbyqxmd.com/read/26780945/patient-perceived-benefit-in-facial-aesthetic-procedures-face-q-as-a-tool-to-study-botulinum-toxin-injection-outcomes
#20
Brian L Chang, Anthony J Wilson, Anthony J Taglienti, Catherine S Chang, Nancy Folsom, Ivona Percec
BACKGROUND: There are numerous methods of assessing patient satisfaction with botulinum toxin type A neuromodulation of the glabellar rhytids. As the use of aesthetic neuromodulation increases both in breadth and number of procedures, there is a need for more comprehensive tools to evaluate patient-reported outcomes. The FACE-Q is a recently validated patient-reported outcome instrument that can be used to measure patient perceptions of botulinum toxin type A neuromodulation. OBJECTIVES: This study used the FACE-Q to assess patient satisfaction following botulinum toxin type A neuromodulation of the glabellar rhytids...
July 2016: Aesthetic Surgery Journal
keyword
keyword
9456
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"